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High grade gliomas (HGG) are one of the most common central nervous system (CNS)
tumors encountered in adults, but they only represent approximately 8–12% of all pedi-
atric CNS tumors. Historically, pediatric HGG were thought to be similar to adult HGG since
they appear histologically identical; however, molecular, genetic, and biologic data reveal
that they are distinct. Similar to adults, pediatric HGG are very aggressive and malignant
lesions with few patients achieving long-term survival despite a variety of therapies. Ini-
tial treatment strategies typically consist of a gross total resection (GTR) when feasible
followed by focal radiotherapy combined with chemotherapy. Over the last few decades,
a wealth of data has emerged from basic science and pre-clinical animal models helping
to better deﬁne the common biologic, genetic, and molecular make-up of these tumors.
These data have not only provided a better understanding of tumor biology, but they have
also provided new areas of research targeting molecular and genetic pathways with the
potential for novel treatment strategies and improved patient outcomes. Here we provide
a review of pediatric non-brainstem HGG, including epidemiology, presentation, histology,
imaging characteristics, treatments, survival outcomes, and an overview of both basic and
translational research. An understanding of all relevant pre-clinical tumor models, includ-
ing their strengths and pitfalls is essential in realizing improved patient outcomes in this
population.
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INTRODUCTION
High grade gliomas (HGG) represent one of the most com-
mon central nervous system (CNS) tumors among adults. This
contrasts signiﬁcantly to the pediatric population where HGG
only comprise approximately 8–12% of all primary CNS tumors
(Bondy et al., 2008). In adults, HGG often arise from a low grade
glioma (LGG) that has undergone malignant transformation, but
this phenomenon is exceedingly rare in pediatric patients (Bronis-
cer et al., 2007). Similar to the adult experience, however, pediatric
HGG are characterized by their aggressive clinical behavior and
account for a signiﬁcant amount of morbidity and mortality
among children with brain tumors. HGG typically arise from
astrocytic origins, including glial, oligodendrocytes, and ependy-
mal cells (Louis et al., 2007). These tumors are classiﬁed by the
World Health Organization (WHO) as either grade III or IV
meaning that they are highly malignant tumors with character-
istic ﬁndings such as hypercellularity, nuclear atypia, and high
mitotic activity with or without microvascular proliferation and
pseudopalisading necrosis (Kleihues et al., 2007; Louis et al., 2007).
HGG include a variety of heterogeneous lesions with differing
histologies, but the most common histologies are anaplastic astro-
cytoma (WHO Grade III) and glioblastoma multiforme (GBM;
WHO grade IV). Despite numerous treatment approaches, out-
comes have remained dismal with most series showing 5-year
survival outcomes ranging from 15 to 35% and the far majority of
children succumbing to their disease (Broniscer and Gajjar, 2004;
Finlay and Zacharoulis, 2005; Broniscer, 2006; Cohen et al., 2011).
Although there truly is no one accepted standard of care and
treatment algorithms can vary, most experts agree that a gross
total resection (GTR) followed by focal irradiation to the tumor
bed plus additional chemotherapy is an appropriate treatment
approach (Fangusaro, 2009; Jones et al., 2012).
As with most tumor types, one proposed key to improving sur-
vival outcomes is a better understanding of tumor biology. Since
pediatric HGG histologically resemble adult HGG, historically, it
was believed that these were similar tumors. New biologic, molec-
ular, and genetic data suggest that pediatric HGG are distinct from
adult HGG (Jones et al., 2012). In fact, over the last few decades,
signiﬁcant data has emerged greatly enhancing our understanding
of pediatric HGG biology. These data have given rise to unique
research opportunities that can exploit our biologic knowledge
of these tumors in an effort to utilize novel biologically targeted
agents with the potential to improve patient survival. Here we
present an overview of non-brainstem pediatric HGG and review
the basic epidemiology, presentation, histology, imaging char-
acteristics, treatment strategies, and survival outcomes. We also
review the current understanding of pediatric HGG biology and
current models utilized to assess these tumors.
EPIDEMIOLOGY AND ETIOLOGY
According to the Central Brain Tumor Registry of the United
States (CBTRUS) for the years 2004–2008, approximately 7% of
all reported brain tumors occurred in children 0–19 years old
(y/o). Among children 0–19 y/o the overall total incidence of HGG
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(including anaplastic astrocytoma, anaplastic oligodendroglioma,
glioblastoma, mixed glioma, and malignant glioma) is approxi-
mately 0.85 per 100,000 (CBTRUS, 2012). Most series estimate
that HGG represent approximately 8–12% of all childhood CNS
tumors and thedistributionbetweenmales and females is relatively
equal (Finlay and Zacharoulis, 2005; Broniscer, 2006). Although
they can occur anywhere within the CNS, the most common loca-
tion is within the supratentorial compartment when brainstem
lesions are excluded (Broniscer and Gajjar, 2004). It is estimated
that 35–50% are located within the cerebral hemispheres with a
smaller percentage emanating from the thalamus, hypothalamus,
third ventricle, and basal ganglia. Primary spinal cord lesions are
much less commonwith an incidence of approximately 3% in chil-
dren (Wolff et al., 2012). Non-brainstem infratentorial lesions are
most commonly seen in younger children as compared to adoles-
cents and young adults (Fangusaro, 2009). The highest incidence
of supratentorial HGG among children is in patients 15–19 y/o
with a median age of approximately 9 y/o; however, HGG can
be seen in any age group starting from in utero and early infancy
through young adulthood suggesting multiple contributing fac-
tors to their etiology (Seker and Ozek, 2006; Hou et al., 2008;
Milano et al., 2009).
A variety of hypotheses have been postulated in an effort to
more fully understand the etiology of pediatric CNS tumors,
including HGG, but the cause of the majority is greatly unknown.
There are a few established risk factors that predispose children
to the development of HGG. One well understood risk factor is
exposure to ionizing radiation, typically for the treatment of a
previous oncologic condition, such as acute leukemia. A study
performed at St. Jude Research Children’s Hospital identiﬁed a
dose-dependent effect on tumor development from previous radi-
ation exposure (Walter et al., 1998). The study also concluded that
children who received radiation before the age of 6 y/o had the
highest risk of developing a secondary malignancy (Walter et al.,
1998). These ﬁndings were further supported in a larger subse-
quent cohort from the Childhood Cancer Survivor Study (Neglia
et al., 2006). Most other exposures thought possibly related to
brain tumor development (cell phone use, infections, trauma, and
toxins) have not consistently been shown statistically related to
brain tumor development suggesting that the true etiology is most
likely multifactorial (Baldwin and Preston-Martin, 2004).
There are also rare genetic diseases that predispose a child to
the development of a HGG. Most of these are inherited defects
in the regulation of cell proliferation and apoptosis typically
caused by germline mutations (Melean et al., 2004). Neuroﬁbro-
matosis type I is an autosomal recessive disorder and the most
common inherited genetic disorder predisposing children and
adults to CNS tumor development. A mutation in the NF-1 gene
results in an absence of a protein called neuroﬁbromin. Normally,
this protein regulates growth and Ras, a proto-oncogene, so in
its absence, unregulated cell growth and oncogenesis can ensue
(Ward and Gutmann, 2005). Far and away, these patients have
an increased risk of developing LGG within the CNS, typically
the optic pathway, but there are data showing that these patients
are also at an increased risk for developing HGG (Rosenfeld
et al., 2010). Another disorder associated with HGG develop-
ment is Li-Fraumeni syndrome. In Li Fraumeni, patients exhibit
a defect in TP53 gene which encodes for the checkpoint protein,
p53. TP53 normally acts as a tumor suppressor gene by inducing
pathways that cause cell cycle arrest, apoptosis, and inhibit angio-
genesis (Melean et al., 2004). A mutation in this system leads to
unregulated cell proliferation and an increased risk of malignant
transformation. These patients can develop a variety of malignan-
cies, typically at a younger age, including HGG (Varley, 2003).
Other rare genetic disorders that increase the risk of CNS tumor
development include Turcot’s syndrome, Tuberous sclerosis, and
von Hippel–Lindau disease (Hamada et al., 1998; Varley, 2003;
Melean et al., 2004). PatientswithTurcot’s syndrome typically have
a defect in the adenomatous polyposis coli (APC) gene and/or a
mutation in DNA mismatch repair (MMR) genes predisposing
them to the development of multiple colorectal adenomas, col-
orectal adenocarcinoma, and primary brain tumors (Itoh et al.,
1993; Melean et al., 2004). The MMR mutations are thought to be
associatedwith the development of HGG in these patients whereas
theAPC defects aremore closely associated withmedulloblastoma
development (Melean et al., 2004). Although tuberous sclerosis
and von Hippel–Lindau disease both predispose patients to CNS
tumordevelopment, these patients typically donot developHGGs.
These genetic disorders have contributed greatly to our under-
standing of tumor biology and development; however, they can
be linked to only a fraction of HGG cases in children with the
remainder (and majority) of cases having no known identiﬁable
cause.
CLINICAL PRESENTATION, DIAGNOSIS, AND PROGNOSTIC
FACTORS
Children presenting with a new diagnosis of a HGG often develop
the same symptoms common to many newly diagnosed CNS
tumors. These presenting signs are often due to increased intracra-
nial pressure including persistent headaches, behavior changes,
early morning nausea/emesis, diplopia, and papilledema. Patients
may also present with more speciﬁc localizing symptoms such as
focal motor deﬁcits, hemiplegia, pyramidal tract ﬁndings, dysme-
tria, and chorea depending upon the tumor’s location (Fangusaro,
2009). As compared to LGG, the typical duration of symptoms
prior to presentation is often much shorter in children with HGG.
This is hypothesized to be due to the increasedmitotic activity and
faster growth rate of these tumors leading to more rapid invasion
of the adjacent normal brain tissue (Reddy and Wellons, 2003;
Reulecke et al., 2008). Although patients with HGG can develop
seizures, this is not a common presentation at diagnosis. Seizures
in the setting of a HGG often occur when the tumor invades the
temporal lobe, a common seizure focus. Seizures are a muchmore
common presentation in speciﬁc low grade CNS tumors such
as ganglioglioma and dysembryoplastic neuroepithelial tumors
(DNET; Khajavi et al., 1995; Weissman et al., 1996). As com-
pared to older children, infants and young children often present
with non-speciﬁc ﬁndings such as failure to thrive, lethargy, nau-
sea/emesis, andmacrocephaly oftenmaking the diagnosis difﬁcult
as many of these symptoms may go unnoticed or are attributed
to other common childhood illnesses, such as a viral infection
(Reddy andWellons, 2003).
The ﬁrst diagnostic tool of choice in most children suspected
of having an intracranial process is a non-contrast computerized
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tomography (CT) scan. This imaging technique is quick, often
eliminating the need for sedation in young children, and it is
a good screening tool to evaluate for hydrocephalus and acute
CNS hemorrhage. CT may also help identify a space-occupying
lesion/mass. As with most pediatric CNS tumors, however, mag-
netic resonance imaging (MRI) is the imaging modality of choice.
MRI not only provides a clearer picture regarding tumor location
and invasion into surrounding brain, but it is an essential tool nec-
essary for neurosurgical and radiation planning. Although there
is no one speciﬁc MRI ﬁnding that can distinguish a HGG from
other pediatric CNS tumors, there are some characteristics that
are common to HGG that may help guide the differential diag-
nosis. Typically, HGG have less distinct and irregular borders as
compared to otherCNS tumors. Theymay havemass effect on sur-
rounding brain structures and nodular enhancement. Classically,
these lesions are hypo-intense on T1- and hyper-intense on T2-
weightedMRI sequences and induce signiﬁcant edema as noted on
ﬂuid attenuation inversion recovery (FLAIR) images (Panigrahy
and Bluml, 2009). Although contrast-enhancement is commonly
seen in supratentorial HGG, the amount and degree of enhance-
ment does not always correlate to tumor grade (Warren, 2008).
Most HGGs are locally invasive and rarely present with distant
metastases or leptomeningeal spread (Broniscer and Gajjar, 2004;
Fangusaro, 2009). Therefore, imaging of the spinal axis in patients
with intracranial lesions is physician dependent, but many clini-
cians will obtain a complete spine MRI at diagnosis as a baseline
or if speciﬁc symptoms warrant assessment.
Advanced imaging techniques are currently being researched
in an effort to help guide diagnosis and treatment strategies. For
example, perfusion-weighted MRI is a non-invasive technique
that helps determine tumor angiogenesis and capillary perme-
ability. HGG commonly demonstrate increased blood ﬂow to
a tumor lesion demonstrated on this modality (Panigrahy and
Bluml, 2009). Magnetic resonance spectroscopy (MRS) is another
modality that is being increasingly evaluated. MRS utilizes imag-
ing to understand themetabolic proﬁle of a speciﬁc area of interest
within the brain. In gliomas, as the tumor grade increases to amore
malignant variant, there is an increase in the choline to N-acetyl
aspartate (NAA) ratio reﬂecting the increased metabolic activity
present in higher grade lesions (Lemort et al., 2007; Panigrahy
and Bluml, 2009). These are just a couple of the many ongoing
advanced imaging techniques being studied. None of the advanced
imaging techniques evaluated thus far can conclusively diagnose a
speciﬁc histology, and therefore, a biopsy or surgical resection is
recommended whenever possible to establish a diagnosis.
Surgical resection is important for many reasons, including
establishing a diagnosis of HGG, relieving intracranial pressure,
and contributing to prognosis. Independent from tumor location
and speciﬁc histology, the amount of surgical resection is one of
the most important clinical prognostic factors identiﬁed to date
in children with supratentorial HGG (Finlay et al., 1995; Broniscer
and Gajjar, 2004). The Children’s Cancer Group (CCG) study-945
showed that those children with HGG who underwent a surgical
resection of 90% or greater had a progression-free survival (PFS)
of 35 ± 7% as compared to a 5-year PFS of 17 ± 4% in patients
who did not (Finlay et al., 1995). Therefore, every attempt should
be made at a complete surgical resection when safe and feasible
in an effort to maximize patient survival. Unfortunately, complete
resection may not be possible in many cases, especially in patients
harboring tumors invading critical structures, those with midline
tumors and infratentorial tumors involving the cerebellum and
brainstem. Histologic grade has proven prognostic in some series
whereas thosepatientswith aWHOgrade III tumorhave improved
survivals as compared to those with WHO grade IV tumors. In
the aforementioned CCG-945 trial, patients with an anaplastic
astrocytoma (WHO grade III) had statistically improved survival
with estimated 5-year PFS and overall survival (OS) of 28 and
29%, respectively, as compared to patientswithGBM(WHOgrade
IV) who had a 5-year PFS and OS of 16 and 18%, respectively
(Finlay et al., 1995).
The CCG-945 trial also looked at a variety of molecular and
cytogenetic markers in an effort to better deﬁne prognostic vari-
ables in pediatric HGG. An analysis of p53 revealed that those
patients with overexpression of p53 and/or amutation in theTP53
gene had signiﬁcantly lower PFS as compared to children who had
neither of these ﬁndings. Abnormalities of p53 were most com-
monly seen inWHO grade IV tumors; however, p53 was shown to
be an independent prognostic factor regardless of histologic grade
(Pollack et al., 2002). A follow-up analysis of O6-methylguanine-
DNA methyltransferase (MGMT) status in this same group of
patients revealed a statistically worse outcome in children with
overexpression of MGMT (Pollack et al., 2006).
Interestingly, there appears to be a subset of younger children
who harbor histologically proven HGG that have a more indolent
course as compared to older children. It is believed that the biol-
ogy of these tumors is distinct despite the histologic similarities.
There is data in a small number of cases showing that infant HGG
appear to lack HOXA9/HOXA10 which are thought important for
self-renewal (Jones et al., 2012). HOXA9/HOXA10 have been asso-
ciated with more malignant variants with poor prognosis in some
adults and older children with HGG (Jones et al., 2012). This may
help explain why these young children with HGG have seemingly
less aggressive disease. In a prospective French study evaluating the
use of chemotherapy in young children less than 5 y/o with newly
diagnosedHGG,5-year PFSwas 35%and 5-yearOSwas 59%,with
a median follow-up of 5.2 years (Dufour et al., 2006). In a sepa-
rate retrospective study performed at St. Jude Research Hospital
reviewing the clinical characteristics and survival in childrenunder
3 y/o withHGG, 5-year event-free survival (EFS) andOSwere 28.6
and 66.3%, respectively (Sanders et al., 2007). These outcomes are
far superior to those published in older children with HGG again
suggesting that these tumors may be distinct (Finlay et al., 1995;
Broniscer and Gajjar, 2004; Cohen et al., 2011). Other groups have
shown this same phenomenon whereby younger children have an
improved survival outcome even when utilizing radiation-sparing
treatment strategies (Geyer et al., 1995; Duffner et al., 1996). It
is unclear, however, if it truly is a speciﬁc age that is prognos-
tic or if younger children simply develop HGG tumors that have
unique biologic and molecular characteristics that confer a better
prognosis.
TREATMENT STRATEGIES AND OUTCOMES
The initial treatment strategy for a child with a newly diag-
nosed HGG is to attempt a maximal safe surgical resection. This
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recommendation is based upon the data from the previouslymen-
tioned CCG-945 showing that amount of surgical resection is a
prognostic variable (Finlay et al., 1995). Even when a complete
radiographic GTR is achieved, it is understood that microscopic
tumor cells are still present. This is due to the inﬁltrative nature
of these lesions making it virtually impossible to achieve a GTR
with clear surgical margins without risking signiﬁcant morbidity
(Broniscer and Gajjar, 2004; Fangusaro, 2009). Additional ther-
apy is necessary in an attempt to prevent the high likelihood
of local recurrence. Radiation therapy has become the main-
stay of therapy, particularly for those children older than 3 y/o
with newly diagnosed HGG. Since younger children are more
susceptible to the negative deleterious effects associated with radi-
ation therapy and they seem to harbor more indolent tumors,
they are often treated with chemotherapy alone and radiation-
sparing approaches (Geyer et al., 1995; Duffner et al., 1996; Dufour
et al., 2006; Sanders et al., 2007). For older children, focal radio-
therapy with a margin around the tumor bed has become the
standard. Previous studies have shown that there is no role for
whole brain radiotherapy in patients with localized HGG (Buck-
ner et al., 2007). Typically, the conventional dosing for a child with
a newly diagnosed HGG is 50–60 Gy delivered in daily fractions
of approximately 180–200 cGy over a 6 week period. Alternative
radiotherapy techniques such as hyper- and hypo-fractionation
have not consistently proven to be statistically beneﬁcial in chil-
dren with HGG and are typically not utilized outside of a clinical
trial setting (Fallai and Olmi, 1997).
Chemotherapy was ﬁrst introduced into the treatment schema
for children with newly diagnosed HGG in the 1970s. Despite
a few publications reporting the additional beneﬁt to survival
as compared to radiation therapy alone, its exact role and true
survival beneﬁt remain disputed. In the CCG-943 trial, children
with newly diagnosed HGG were randomized to receive either
focal radiation therapy alone to a dose of 54 Gy or the same
radiotherapy with a combination of concomitant and mainte-
nance chemotherapy. Patients randomized to receive chemother-
apy received weekly vincristine during radiation followed by
eight maintenance chemotherapy cycles consisting of prednisone,
lomustine, and vincristine (pCV) each given approximately 6
weeks apart (Sposto et al., 1989). Five-year EFS was 46% in the
chemotherapy treated group versus 18% in the radiation alone
group which was a statistically signiﬁcant difference; however, a
central pathology review performedmany years later revealed that
many of the patients included in this study harbored LGGs (Sposto
et al., 1989; Finlay and Zacharoulis, 2005). Despite this, there still
appeared to be a statistical beneﬁt with the addition of chemother-
apy to radiotherapy in patients with GBM (WHO grade IV). Since
this trial, the addition of chemotherapy to radiotherapy has been
adopted by many as the accepted “standard of care” for children
with newly diagnosedHGG.Unfortunately, numerous subsequent
combination studies completed over the last 40 years have never
reached the outcomes achieved by the CCG-943 trial, suggest-
ing that the addition of LGGs in this cohort skewed the survivals
reported.
The immediate successor to CCG-943 was the CCG-945 trial.
In CCG-945, children with HGG were randomized to one of two
chemotherapy regimens in addition to focal radiotherapy. The
conventional arm was the same chemotherapy given in the CCG-
943 trial (pCV) and the experimental arm was the so called “8 in
1” regimen, a combination of eight agents all given within a short
time period (prednisone, lomustine, vincristine, hydroxyurea,
cisplatin, cytarabine, dacarbazine, and procarbazine). Patients
assigned to the “8 in 1” arm received two cycles of pre-radiation
chemotherapy, and those patients less than 2 y/o were non-
randomly assigned to the“8 in 1” regimen. There was no statistical
difference between the two arms and the outcomes were worse as
compared to the previous CCG-943. Five-year PFS was 26 ± 8%
in the conventional arm versus 33 ± 8% in the experimental arm
(Finlay et al., 1995).
There have been a variety of trials conducted in pediatric
patients utilizing adiverse groupof biologic and chemotherapeutic
agents in combinationwith focal radiotherapy. All havehad similar
survival results, againnever achieving theoutcomes reported in the
original CCG-943 trial. In 2005, Stupp and colleagues published
data showing that the addition of temozolomide to radiotherapy
for newly diagnosed GBM in adult patients resulted in a clinically
meaningful and statistically signiﬁcant survival beneﬁt with min-
imal additional toxicity as compared to radiation alone (Stupp
et al., 2005). This agent was an oral alkylating agent and overall
well tolerated, so many experts had high hopes for its application
in the pediatric HGG population. The adult trial prompted the
development of a pediatric trial, the Children’s Oncology Group
(COG)ACNS-0126 study. ACNS-0126was a phase II trial whereby
children with newly diagnosed HGG received daily temozolomide
during radiotherapy followed by maintenance temozolomide.
There was not a randomization to radiation alone, since the
previous CCG-943 trial had already established a beneﬁt utiliz-
ing chemotherapy. Temozolomide showed no survival beneﬁt as
compared to historic controls (Cohen et al., 2011). In truth, the
pediatric trial did not ask the same question as the successful adult
trial comparing to radiation alone, but the results were still no
better than the numerous preceding pediatric HGG trials. Despite
this, the improved tolerability and ease of administration have lead
many clinicians to continue to utilize this strategy when treating
newly diagnosed patients who are not enrolled on a clinical trial
(Fangusaro andWarren, 2012).
There has also been an attempt to overcome the resistance
to alkylators apparent in some patients with HGG. For exam-
ple, the disappointing responses to temozolomide observed in
children with HGG are in part thought attributable to overex-
pression of DNA repair proteins, particularly MGMT (Donson
et al., 2007). This has led to clinical trials attempting to over-
come this resistance in an effort to achieve a therapeutic response.
In a study performed by the Pediatric Brain Tumor Consor-
tium (PBTC), pediatric patients with recurrent or progressive
HGG were treated with the combination of O6-benzylguanine
(O6BG) and temozolomide. Forty-one patients were evaluable for
response, including 25 patients with HGG. Although the combi-
nation was tolerable, it did not achieve the target response rate
for activity (Warren et al., 2012). This population of patients with
recurrent HGG has proven exceedingly difﬁcult to treat with very
few treatment options providing clinically meaningful responses.
There are fewer options and an even worse prognosis for chil-
dren with recurrent HGG, with almost all children succumbing
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to their disease. One approach to treating children with recurrent
HGG has been the use of high dose chemotherapy followed by
autologous hematopoietic cell rescue. Although this is still con-
sidered controversial and is not universally accepted, the literature
does suggest there may be a role for this strategy in a speciﬁc
group of children with recurrent disease (Guruangan et al., 1998;
Finlay et al., 2008). In a study by Finlay et al. (2008), 27 chil-
dren with recurrent malignant astrocytomas received myeloabla-
tive chemotherapy followed by autologous marrow rescue with
thiotepa and etoposide-based chemotherapy regimens. Five of 27
children survived event-free from 8.3 to 13.3 years at the time
of publication. Another study by Guruangan et al. (1998) evalu-
ated the outcome of myeloablative chemotherapy and autologous
bone marrow rescue with or without radiotherapy in children
younger than 6 years of age with a variety of recurrent malignant
brain tumors who had not previously received irradiation. Twenty
patients with recurrent brain tumors were enrolled. Ten of 20
(50%) patients, including three patients with HGG were alive and
disease free at a median of 37.9 months at the time of publication.
They concluded thatmyeloablative chemotherapywith autologous
hematopoietic cell rescue followed by additional external-beam
irradiation appeared to be an effective retrieval therapy for
some young children with recurrent brain tumors (Guruangan
et al., 1998). These data suggest again that there may be a sub-
group of children with recurrent HGG for which this strategy is
appropriate.
In adult HGG, the use of bevacizumab (BVZ), an anti-
angiogenic agent that blocks vascular endothelial growth factor
(VEGF), has shown promising results and a survival beneﬁt in
patients with recurrent HGG (Narayana et al., 2009; Huylebrouck
et al., 2012; Morris, 2012). These ﬁndings led to the development
of a pediatric trial within the PBTC-022 utilizing BVZ and CPT-
11 in children with recurrent CNS tumors, including a HGG and
diffuse intrinsic pontine glioma (DIPG) strata (Gururangan et al.,
2010). Thirty-one evaluable patients received a median of two
courses of BVZ plus CPT-11. There were no sustained responses
in either HGG or DIPG. Median time to progression was 127 days
for HGG patients and 6-month PFS was 41.8%. Although the reg-
imen was well-tolerated, it showed minimal efﬁcacy in children
with recurrent HGG (Gururangan et al., 2010).
Bevacizumab has also recently been evaluated in up-front stud-
ies for adults with newly diagnosedHGG.An adult feasibility study
evaluating the use of BVZ given concurrently with radiation ther-
apy and daily temozolomide revealed that the combination was
feasible. Radiographic responses were noted in 13 of 14 assessable
patients (Narayana et al., 2008). In another pilot Phase II study
of BVZ in combination with temozolomide and regional radia-
tion therapy for up-front treatment of adult patients with newly
diagnosed GBM, the interim analysis of 10 patients reported that
the observed toxicities were acceptable to continue enrollment
toward the overall target group of 70 patients. Also, the prelimi-
nary efﬁcacy analysis showed encouraging PFS (Lai et al., 2008).
There are also ongoing studies evaluating the use of BVZ in chil-
dren with newly diagnosed HGG as well, including the currently
openCOGACNS-0822 trial. This trial is a randomized Phase II/III
trial whereas patients with newly diagnosed HGG will be assigned
to one of three chemo-radiotherapy arms, including vorinostat
(a histonedeacetylase inhibitor) given concurrentlywith radiation,
temozolomide given with radiation, or BVZ given with radiation.
All three arms are followed by the same maintenance chemother-
apy combination of BVZ and temozolomide (ClinicalTrials.gov,
2010–2012b). This trial is currently accruing patients.
Several biologically targeted agents are under investigation in
combination with radiation in newly diagnosed patients and as
salvage therapy in childrenwith recurrent disease, including recep-
tor tyrosine kinase inhibitors, histone deacetylase inhibitors, and
integrins. One speciﬁc targeted therapy that has shown promising
pre-clinical data is polyADP ribose polymerase (PARP) inhibitors.
PARP1 is a protein involved in single-strand DNA break repair.
Increased PARP1 expression has been observed in HGG as com-
pared to non-neoplastic brain tissue. PARP inhibition potentially
enhances sensitivity of tumor cells to DNA damaging agents,
including radiotherapy (vanVuurden et al., 2011). Currently, there
are ongoing trials in pediatric HGG exploring the use of PARP
inhibitors in children with both newly diagnosed and recurrent
HGG and DIPG (ClinicalTrials.gov, 2009–2012b, 2012). Many
of the data on speciﬁc agents is forthcoming, and some experts
suggest their role may be best suited as maintenance therapy in
the setting of minimal residual disease (Herrington and Kieran,
2009). Another novel approaches toHGG treatment is convection-
enhanced delivery (CED). CED utilizes a surgical technique to
place a catheter locally and directly into the tumor or tumor
resection cavity and directly infuses agents such as chemother-
apy, cytotoxic proteins and other biologically targeted agents
under a positive pressure gradient (White et al., 2012a,b). Tri-
als utilizing this technique in children with HGG are ongoing
(ClinicalTrials.gov, 2006–2012, 2009–2012a).
Immunotherapy has also become an attractive area of research
among adult and pediatric HGG. The CNS has long been con-
sidered an immunologically privileged site, but it is unclear what
limits immunoreactivity within the brain. There has been increas-
ing evidence that during times of CNS insult, there is an increase in
the number of lymphocytes within the CNS (Horwitz et al., 1999).
In a study evaluating adult HGG in humans, tumor inﬁltrating
lymphocytes (TIL) and regulatory T cells (Treg) were present at a
statistically higher frequency as compared to control samples. This
increase in lymphocytes was also noted in the peripheral blood of
glioma patients as compared to control patients. It is hypothe-
sized that an increase in the Treg cells in the CNS of brain tumor
patients may induce a blockade of the natural immune-mediated
anti-tumor response. It has been proposed that by countering
or depleting these cells, a more vigorous immune-mediated anti-
tumor response may be achievable (El Andaloussi and Lesniak,
2006). This hypothesis was evaluated in a murine model and
showed prolonged survival in mice by depleting CD4+CD25+
Treg cells (El Andaloussi et al., 2006). Also, by utilizing antibod-
ies that counter this blockade of the immune system, mice with
established malignant gliomas achieved 80% long-term survival
and evidence of enhanced immunologic response as compared
to controls (Fecci et al., 2007). Immune therapies, including vac-
cine therapies are being increasingly utilized in both adult and
children with newly diagnosed and recurrent HGG (Okada et al.,
2003, 2007).Many of these trials in pediatrics are still ongoingwith
results forthcoming (ClinicalTrials.gov, 2005–2010, 2010–2012a).
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BIOLOGY, GENETICS, AND MOLECULAR CHARACTERISTICS
Over the last decade, there is an increasing understanding of the
molecular, biologic, and geneticmake-up of pediatricHGG. These
data have not only helped us to better delineate differing groups
of tumors among HGG, but they have allowed development of
speciﬁc targeted therapies that manipulate our understanding of
tumor-related aberrations and oncologic pathways. One of the
most common genetic abnormalities in adult HGG is the ampli-
ﬁcation of epidermal growth factor receptor (EGFR; Libermann
et al., 1985; Barker et al., 2001). Although overexpression of the
EGFR protein is sometimes seen in pediatric supratentorial HGG,
the genetic ampliﬁcation is quite rare (Libermann et al., 1985; Bre-
del et al., 1999). There are some data indicating that its expression
may be a prognostic marker in speciﬁc cohorts of patients treated
with EGFR-targeting agents (Geoerger et al., 2011). Mutations in
the p53 pathway are a much more common ﬁnding in pediatric
HGG. Both overexpression of p53 andmutations in theTP53 sup-
pressor gene can lead to defects in this pathway and tumorigenesis.
Alterations in this pathway have been shown to be prognostically
relevant in numerous studies (Pollack et al., 2002; Rood and Mac-
Donald, 2005). Many of the alteration/abnormalities identiﬁed
in adult HGG such as retinoblastoma gene mutation, ampliﬁca-
tions of MYC, MYCN, CDK6, CCND2, deletion of CDKN2C and
PTEN mutations are less well understood and overall seemingly
less prevalent among children (Broniscer and Gajjar, 2004; Rood
and MacDonald, 2005; Jones et al., 2012).
Interestingly, as compared to adult HGG, pediatric HGG have
much fewer DNA copy number alterations (Jones et al., 2012).
There have been a few consistent chromosomal abnormalities
identiﬁed in pediatric HGG, including gains at 1p, 2q, and 21q
as well as losses noted at 6q, 4q, 11q, and 16q (Rickert et al., 2001;
Wong et al., 2006; Bax et al., 2010; Paugh et al., 2010). In par-
ticular, as compared to the adult HGG, pediatric HGG seem to
possess a statistically higher incidence of gains at 1q and losses
at 16q and 4q (Wong et al., 2006; Bax et al., 2010; Paugh et al.,
2010; Qu et al., 2010; Schiffman et al., 2010; Barrow et al., 2011;
Schwartzentruber et al., 2012). Among the numerous focal genetic
alterations elucidated in pediatric HGG, platelet-derived growth
factor receptor A (PDGFRA) ampliﬁcation is by far themost com-
mon genomic event identiﬁed. This ampliﬁcation seems to occur
most often in older children andmay have some prognostic signif-
icance (Bax et al., 2010; Paugh et al., 2010; Qu et al., 2010). Another
mutation observed in about 10% of pediatric HGG is the V600E
point mutation in BRAF (Nicolaides et al., 2011). Interestingly,
this seems to be associated with tumors that also possess PDGFRA
ampliﬁcation (Jones et al., 2012). Distinct from the BRAFV600E
mutation in many LGG, however, CDKN2A/CDKN2B mutations
are more common in these HGG which may help explain why
these lesions behave more malignant compared to their LGG
counterparts (Jones et al., 2012).
A recent large study evaluated 78 pediatric HGG and DIPG
utilizing high-resolution analysis of genomic imbalances using
single nucleotide polymorphismmicroarray analysis. The ﬁndings
were then compared to data currently understood regarding adult
HGG. There were signiﬁcant differences in copy number alter-
ations that distinguished pediatric from adult HGG (Paugh et al.,
2010). PDGFRAwas the predominant target of focal ampliﬁcation
in childhood HGG as mentioned above. Speciﬁc gene expression
analyses identiﬁed a possible role for disrupted PDGFRalpha sig-
naling in pediatricHGG. These data again highlighted the growing
wealth of information supporting the distinctness between adult
and pediatric HGG (Paugh et al., 2010). This group also did not
identify a signiﬁcant number of isocitrate dehydrogenase I (IDHI)
mutations in pediatric HGG which have been shown to be quite
prevalent and prognostic among adult HGG patients (Horbinski
et al., 2009; Labussiere et al., 2010; Paugh et al., 2010). Interest-
ingly, there were some pediatric cases that did cluster with and
have signatures more consistent with adult cases suggesting that
HGG is a spectrum of diseases that can cross age groups with
some subgroups more prevalent in pediatrics and some more
common in adults (Paugh et al., 2010). The study also found that
there were three distinct subgroups of pediatric HGG identiﬁed
utilizing unsupervised hierarchical clustering, described as HC1,
HC2, and HC3. Analyses of the abnormalities most common in
each subgroup revealed that HC1 overexpressed cell cycle regu-
lation genes. HC2 overexpressed neuronal differentiation genes
and HC3 overexpressed cellular matrix–receptor interactions and
cell adhesion genes (Paugh et al., 2010). Similar to other tumors,
like medulloblastoma, for example, identifying speciﬁc subgroups
within pediatric HGG is becoming increasingly important as an
attempt is made to prognosticate and ﬁnd targeted therapies that
are relevant (Northcott et al., 2012; Taylor et al., 2012). Clini-
cally, there already is a distinct difference noted between younger
children and older children within pediatric HGG as described
previously.
In another large study, the exomes of 48 pediatric HGG were
sequenced. Somatic mutations in the H3.3-ATRX-DAXX chro-
matin remodeling pathway were found in 44% of the samples.
Mutations in H3F3A were observed in 31%, which was iden-
tiﬁed to effect key regulatory post-translational modiﬁcations
(Schwartzentruber et al., 2012). Mutations in ATRX (alpha-
thalassemia/mental retardation syndrome X-linked) and DAXX
(death-domain associated protein), were identiﬁed in 31% of
tumor samples and TP53 mutations were found in 54% of all
cases. TP53 mutations were found at a higher percent in samples
that also had H3F3A and/or ATRX mutations. When the group
screened a large separate cohort of gliomas of various grades,
they found that the H3F3A mutation appeared to be speciﬁc for
GBM (Schwartzentruber et al., 2012). They concluded that defects
within the chromatin architecturemaybe critical to pediatricGBM
development (Schwartzentruber et al., 2012).
CONCLUSION: CHALLENGES AND FUTURE DIRECTIONS
Despite the wealth of data regarding the biologic and genetic
make-up of pediatric HGG, there remain numerous barriers to
understanding the best treatments strategies in children. First,
as compared to adults, the number of children with a newly
diagnosed HGG is much smaller (CBTRUS, 2012). This makes
conducting statistically relevant Phase I and Phase II trials of new
agents more difﬁcult (Kauffman, 2000). Also, oral medications are
often a challenge with younger children and sometimes speciﬁc
pediatric formulations are necessary (liquid, for example) which
may not be readily available (Abdel-Rahman et al., 2007). The time
to develop a trial and obtain appropriate approval in addition to
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the time necessary to enroll patients and complete a trial often
lags behind emerging biologic data. Questions and hypotheses
that were novel at the time a trial was conceived may no longer be
relevant once a trial is completed. Also, there are limited numbers
of available agents and delivery of these agents into the CNS is
sometimes fraught with toxicity not typically seen outside of the
CNS. Historically, agents are ﬁrst tested in adults prior to develop-
ing Phase I clinical trials in children (Abdel-Rahman et al., 2007).
Since it is clear that HGG is distinct in these two populations,
simply adopting the adult paradigm may not be the most effect
strategy to make advances as witnessed by numerous previous
pediatric trials that have utilized this approach (Abdel-Rahman
et al., 2007; Gururangan et al., 2010; Cohen et al., 2011).
Separate from the clinical challenges, there are also difﬁcul-
ties within the basic and translational science for pediatric HGG.
Unfortunately, some pre-clinical models have been fraught with
pitfalls such as tumors that do not mimic human tumor biol-
ogy, lack of a human microenvironment and poor translation
of promising pre-clinical results (Huszthy et al., 2012). It has
become increasingly important to begin developing animal mod-
els that more closely resemble the distinct variants of pediatric
HGG in order to better mimic the human experience. No cur-
rent animal model is completely identical to the human in vivo
experience; however, current models are far superior to historic
models. For example, historic xenografts derived from chemically
inducedmodels or derived from normal glial cells manipulated by
media do not reﬂect the geneticmake-up and variability of human
glioma. Current techniques of developing xenografts from neuro-
sphere cultures derived from human tumor biopsies more closely
recapitulate what is seen in the human, both genetically, pheno-
typically and clinically (Fomchenko and Holland, 2006; Huszthy
et al., 2012). Many of the genetically engineered mouse models
also better reﬂect the invasiveness and genetic make-up of human
tumors. These newer models are allowing researchers to begin
more carefully assessing what leads to malignant transformation
and what characteristics allow cells to become more inﬁltrative
and metastatic (Huszthy et al., 2012). Also, modern labeling tech-
niques have given researchers the ability to more clearly separate
the human-derived tumor from the animal host’s cellular com-
partments and supportivemicroenvironment allowing for a better
understanding of the relationship and interaction between the two
(Niclou et al., 2008; Huszthy et al., 2012). Anothermethod utilized
to circumvent some of the limitations of animalmodels is by direct
injection of human tumor into themouse brain. Then, by utilizing
advanced imaging techniques, one can assess tumor growth, bio-
logic characteristics, and responses to particular therapies (Jones
et al., 2012). Although these models are still fraught with some
limitations, the hope is that they will help decrease unnecessary
human trials in agents that are not promising or tolerated in the
pre-clinical setting.
Advances in technology and basic science methodology has
allowed for high-throughput drug screening utilizing both neuro-
spheres and murine models (Houghton et al., 2007; Morton et al.,
2007; Whiteford et al., 2007). The Pediatric Pre-clinical Testing
Panel (PPTP) is one such endeavor utilizing these techniques to
better understand which speciﬁc therapeutics may be most suited
to further test and develop in pediatric HGG. Currently, the PPTP
has numerous primary pediatric HGG samples grown in mice.
These models have been utilized in an effort to screen and assess
speciﬁc agents alone and in combination (Houghton et al., 2007;
Kolb et al., 2012; Morton et al., 2012). In order to advance our
knowledge of pediatric HGG, we must understand the strengths
andweaknesses of eachmodel utilized. It is essential thatweunder-
stand what speciﬁc information we can learn from each model.
Only then will we derive a better understanding of pediatric HGG
as a whole (Huszthy et al., 2012).
Pediatric HGG is a heterogeneous group of tumors that rep-
resent a fraction of pediatric CNS tumors, but unfortunately,
they account for a signiﬁcant amount of morbidity and mortality
among pediatric brain tumor patients. These tumors are clearly
distinct from their adult counterparts and yet still possess the same
very aggressive clinical behavior. Current therapies, including
focal radiotherapy utilized in combinations with chemotherapy
and biologically targeted agents are not yet sufﬁcient with the
far majority of patients succumbing to their disease. The hope is
that by obtaining a better understanding of the tumor’s biology
and utilizing a variety of pre-clinical models to recapitulate the
human tumor biology and microenvironment, we will come one
step closer to understanding these tumors more completely. In
doing so, there is the potential to target the “right” pathways in
a speciﬁc tumor and improve patient quality of life and prolong
survival.
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